Donanemab (also called Kisunla and made by Eli Lilly) has been licensed today by the MHRA for treatment of mild cognitive impairment or mild dementia due to Alzheimer’s disease in some adults. It is a ...

Draft guidance issued for consultation recommends the use of 4 AI technologies to help professionals detect fractures in ...

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...

The updated guideline recommends offering a comprehensive falls assessment and management for people who have fallen in the ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Demand for NHS Talking Therapies has reached an all-time high. The service received 1.82 million referrals in 2023/24. This is slightly higher than 2021/2022, and more than double the 884,000 received ...

Belzutifan (Welireg, Merck Sharp & Dohme) is indicated for 'the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology being ...

when localised procedures are unsuitable or undesirable. It is only recommended if the conditions in the managed access agreement for belzutifan are followed. This recommendation is not intended to ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.